Hydrobromide Solid-State Forms for Stable Oral Gamma-Secretase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gamma-secretase inhibitors face challenges in achieving favorable characteristics for therapeutic use, including high affinity, duration of gamma-secretase deactivation, oral bioavailability, tissue distribution, stability, and solid state properties such as chemical stability, thermal stability, solubility, hygroscopicity, and manufacturability, which are crucial for pharmaceutical formulations.
Innovation Solution
Development of various crystalline and amorphous forms of hydrobromide salts of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide, characterized by specific XRPD patterns, melting points, and particle sizes, to address these properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple solid state forms are developed to optimize pharmaceutical properties, then the balance of properties (safety, tolerability, efficacy) is improved, but the device complexity increases
Solution Approach 1:
The patent segments the single compound into multiple solid state forms (crystalline forms A-N and amorphous form), each with distinct properties optimized for different pharmaceutical requirements. This allows selection of the most appropriate form for specific applications while maintaining the core therapeutic activity.
Solution Approach 2:
The patent systematically varies physical and chemical parameters of the solid state forms, including crystal structure, melting point, solubility, hygroscopicity, and particle size. These parameter changes enable optimization of the compound's properties for pharmaceutical formulation and therapeutic performance.
2Stability of the object's composition
If crystalline forms with specific XRPD patterns are developed, then the chemical stability and thermal stability are improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent establishes predetermined crystal structures (Forms A-N) with known and characterized XRPD patterns before pharmaceutical manufacturing. This preliminary characterization allows manufacturers to select and reproduce specific stable forms with controlled properties, reducing manufacturing variability.
Solution Approach 2:
The patent uses XRPD patterns as characteristic fingerprints to identify and differentiate between various crystalline forms. Each form has a unique diffraction pattern that serves as a quality control marker, enabling precise identification and verification of the desired stable form during manufacturing.
3Ease of operation
If solubility and dissolution rate are optimized through solid state form selection, then the oral bioavailability is improved, but the particle size control requirements increase
Solution Approach 1:
The patent exploits changes in solid state parameters (crystalline vs. amorphous, different polymorphs) to fundamentally alter solubility and dissolution characteristics. The amorphous form and certain crystalline forms exhibit enhanced solubility, improving oral bioavailability without requiring extreme particle size reduction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed solid state forms enhance the balance of properties necessary for pharmaceutical formulations, improving safety, tolerability, efficacy, and manufacturability, while providing effective gamma-secretase inhibition.
Implementation Method 1
crystalline Form A, wherein Form A is characterized by an XRPD pattern having peaks at 8.8 ± 0.2, 9.8 ± 0.2, and 23.3 ± 0.2 degrees two theta
Implementation Method 2
the melting point of crystalline Form A is about 254 °C
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.